Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GORDON B MILLS and KAREN H LU.
GORDON B MILLS
Connection Strength
1.557
KAREN H LU
  1. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.209
  2. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov; 22(11):2120-9.
    View in: PubMed
    Score: 0.112
  3. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol. 2012 Mar; 138(3):377-85.
    View in: PubMed
    Score: 0.106
  4. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011 Jul; 1(2):170-85.
    View in: PubMed
    Score: 0.102
  5. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3570-6.
    View in: PubMed
    Score: 0.096
  6. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007 Apr 01; 67(7):3074-84.
    View in: PubMed
    Score: 0.077
  7. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 01; 11(17):6116-26.
    View in: PubMed
    Score: 0.069
  8. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35):12519-24.
    View in: PubMed
    Score: 0.069
  9. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004 Nov; 10(11):1251-6.
    View in: PubMed
    Score: 0.065
  10. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15; 10(10):3291-300.
    View in: PubMed
    Score: 0.063
  11. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3534-45.
    View in: PubMed
    Score: 0.060
  12. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002; 107:61-97.
    View in: PubMed
    Score: 0.053
  13. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. J Natl Cancer Inst. 2020 12 14; 112(12):1190-1203.
    View in: PubMed
    Score: 0.050
  14. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.047
  15. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
    View in: PubMed
    Score: 0.047
  16. Predicting high-risk endometrioid carcinomas using proteins. Oncotarget. 2018 Apr 13; 9(28):19704-19715.
    View in: PubMed
    Score: 0.041
  17. Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.040
  18. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703.
    View in: PubMed
    Score: 0.034
  19. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep; 106(9).
    View in: PubMed
    Score: 0.032
  20. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012 Nov 06; 107(10):1776-82.
    View in: PubMed
    Score: 0.028
  21. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp Clin Cancer Res. 2011 Jan 07; 30:5.
    View in: PubMed
    Score: 0.025
  22. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Int J Mol Epidemiol Genet. 2010; 1(1):1-10.
    View in: PubMed
    Score: 0.023
  23. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med. 2009 Oct 31; 2(4):289-99.
    View in: PubMed
    Score: 0.023
  24. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007; 174:91-100.
    View in: PubMed
    Score: 0.019
  25. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97.
    View in: PubMed
    Score: 0.018
  26. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006 Mar 01; 66(5):2740-8.
    View in: PubMed
    Score: 0.018
  27. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4968-76.
    View in: PubMed
    Score: 0.017
  28. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003 Jul; 90(1):44-50.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.